Infinium Pharmachem is well focused to Iodine chemistry. The company is working as Contract Research and Manufacturing Services (CRAMS), but its domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. Since 2003. the company has been manufacturing & supplying wide range of superior quality iodine derivatives & active pharmaceutical ingredient (API).

The company is also providing fully integrated customized services from R&D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals & various other chemical Industries. The company supplies range of Iodine derivatives on Order to Made basis only. The company also undertakes Non-Disclosure Agreement (NDA) for the development of confidential and rarely available Iodine compounds. 

Business area of the company

The company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.

Milestones

• 2003: Established with a vision to be a globally integrated and admired Pharmaceutical and Healthcare Company.
• 2004: Started iodine derivatives manufacturing plant at Gujarat, India.
• 2010: Set up R&D Unit and Certified as ISO 90001-2008.
• 2011: Penetrated the Pharmaceutical market with the CRAMS model.
• 2014: Upgraded Plant with GMP compliant large scale manufacturing facility.
• 2015: Obtained FDA approval for manufacturing of APIs.
• 2017: Certified as WHO-GMP and ISO 14001-2015.
• 2018: Product Portfolio touched 200+ Iodine Derivatives and 7+ APIs.
• 2019: Expanded reach to over 15+ countries across the globe.
• 2021: Augmentation of production capacity and construction of new Premises.
• 2022: Incorporated subsidiary company in bio-fuel segment for backward integration.
• 2022: Conversion of the company’s status from Private Limited to Limited Company.
• 2023: Infinium Pharmachem shares were listed on the NSE SME (Emerge) platform.
• 2023: Subsidiary Company ‘Infinium Green Energy’, commenced Production facility from May 14, 2023.
• 2024: Commenced construction activities for its new Project (Area comprised of around 1,114 Sq. Mt.) dedicated to manufacturing contrast media raw materials.
• 2025: Entered into a 5-year exclusive distribution agreement with K Sakai & Company Limited
• 2026: Successfully completed and commissioned its new manufacturing facility for contrast media raw materials at GIDC Sojitra, District Anand, Gujarat with effect from January 16, 2026.